HK Stock Market Move | 3D MEDICINES(01244) rose nearly 7%, Enveda received orphan drug status for indications for gastric cancer and gastroesophageal junction cancer.

3D MEDICINES (01244) rose nearly 7%, up 6.77% at the time of publication, to 4.73 Hong Kong dollars, with a trading volume of 911,200 Hong Kong dollars. On the news front, on the evening of December 22, 3D MEDICINES announced that its commercial product Envida (generic name: Envolimab Injection, original research code: KN035) has officially obtained orphan drug qualification for the indications of gastric cancer and gastroesophageal junction cancer. This is the third orphan drug indication successfully approved for Envida after indications for biliary tract cancer and soft tissue sarcoma. This approval is based on the company's Phase II clinical study of Envida for advanced gastric/esophageal junction adenocarcinoma, which has demonstrated clear anti-tumor efficacy with an objective response rate of 60% with the FOLFOX regimen, a disease control rate of 100%, and good safety and tolerability with no adverse events leading to treatment discontinuation or death.